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INTRODUCTION
The guidelines of Global Initiative for Chron-
ic Obstructive Lung Disease (GOLD) define COPD 
as a disease state characterized by airflow limitation 
that is not fully reversible, usually progressive, and is 
ABSTRACT
The remodeling of the bronchial walls is an important process of the pathophysiology of COPD as the ma-
trix metalloproteinase-2 (MMP-2) is shown to play an important role in this process.
The aim of the current study was to elucidate the possible role of MMP2 -1306C>T promoter polymorphism 
as a risk factor for COPD. We genotyped by PCR-RFLP 84 patients with COPD and 71 control individuals.
The genotype, but not the allele distribution, differed between COPD patients and controls (p=0.021 and 
0.602, respectively). Carriers of the variant T allele genotypes (CT+TT) tended to have 1.64-fold higher risk 
for COPD (OR (Odds ratio) =1.64, 95% CI (confidence interval): 0.82-3.26, p=0.164) than those with CC gen-
otype, as that risk was significant in the subset of individuals older than 65 years (OR=4.24, 95% CI:1.31-
13.57, p=0.019). Patients with T containing genotypes (CT+TT) had a later onset of the disease (64.1±7.1 
years) than those with a CC genotype (59.7±9.5 years, p=0.045). The risk for COPD of T carriers (CT+TT) 
was also significant in those individuals without diabetes as co-morbidity. 
In conclusion, our results suggest that the carriers of T allele genotypes (CT+TT) of MMP2 -1306C>T SNP 
may have a higher risk for COPD in advanced age.
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associated with an abnormal inflammatory response 
of the lungs to inhaled noxious particles or gases. 
Subsets of patients may have dominant features of 
chronic bronchitis and/or emphysema. The result 
is airflow obstruction that is not fully reversible (1). 
This pathology is associated with an airway inflam-
matory process characterized by an accumulation of 
inflammatory cells such as macrophages and neutro-
phils (2).
Systemic inflammation is often associated with 
COPD. There has been a growing recognition that 
co-morbidities such as cardiovascular disease, dia-
betes mellitus, cachexia, anemia, osteoporosis, or de-
pression may be present in a greater proportion of 
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patients with COPD  than in  the general population 
(3,4).
The most important risk factor for the develop-
ment of COPD is smoking. However, only 10-20% of 
chronic heavy smokers develop symptomatic COPD, 
which indicates that a difference in susceptibility to 
tobacco smoke injury possibly exist and may be re-
lated to genetic factors (5). Various groups of genes 
are involved in the development of COPD. These 
are some protein-encoding genes with proteolytic 
and anti-proteolytic activity (matrix metalloprotein-
ases, α1-antitrypsin and α1-antichymotrypsin, α2-
macroglobulin), proteins responsible for the increased 
reactivity of the airways, the alveolar surfactant pro-
teins, mediators involved in inflammatory response 
and enzymes involved in the metabolism of toxic sub-
stances in cigarette smoke and antioxidant enzymes 
(5-10). The panacinar form of emphysema is usually 
associated with α1 anti-trypsin deficiency (11).
Тhe development of emphysema usually re-
flects a relative excess of cell-derived proteases that 
degrade the connective tissue of the lung and a rel-
ative decrease of anti-proteolytic defenses. This the-
ory is often referred to as the “protease/antiprotease 
imbalance” hypothesis and involves mainly serine 
proteases such as neutrophil elastase and matrix me-
talloproteinases (MMPs) (initially characterized by 
their capacity to degrade components of the extra-
cellular matrix, ECM) (2,9).
Depending on substrate specificity, amino acid 
similarity and identifiable sequence modules, the 
MMP family can be classified into distinct subclasses: 
collagenases (MMP- l, -8, -13), gelatinases (MMP-2, 
-9), stromelysins (MMP-3, -10, -11), membrane-type 
MMP (MMP-14 to MMP-25), matrilysin (MMP-7), 
and macrophage metalloelastase (MMP-12). MMP 
are synthetized as zymogens (pro-enzymes). The 
MMP activity is tightly regulated on the level of tran-
scription, activation and inhibition by the tissue in-
hibitors of MMPs (TIMPs: TIMP-1, TIMP-2, TIMP-
3, and TIMP-4) and α2-macroglobulin (2,12-15).
MMP-2 (gelatinase A) is primarily expressed in 
mesenchymal cells (mainly fibroblasts) during devel-
opment and tissue regeneration. It is also synthesized 
by neutrophils, macrophages and monocytes – cells 
that participate in the development of the patholog-
ical changes in the lungs in COPD. Due to the air-
way remodeling (synthesis and degradation of ECM) 
there are structural changes, in addition to the in-
flammatory response (16,17).
There are many promoter polymorphisms in 
MMP genes that lead to altered gene expression. The 
expression of MMP-2 is influenced by several pro-
moter SNPs, including MMP2 -1306C>T, however, 
data concerning this SNP as a predisposing factor 
for COPD, are quite limited and with controversial 
conclusions.
In this study we aimed to elucidate the possible 
role of MMP2 -1306C>T promoter polymorphism for 
the risk of COPD.
MATERIALS AND METHODS
Patients
In this study we enrolled 84 patients with 
COPD with different stages of the disease according 
to GOLD (GOLD II, III  and IV) and 71 non-affected 
control individuals from the central Bulgarian region 
of Stara Zagora. In both groups the age of inclusion 
in the study and the smoking status were noted, and 
in the patients’ group age of diagnosis, duration and 
the stages of the disease were reported, too. The data 
of the patients and controls are presented in Table 1.  
The study was approved according to the rules 
in the Medical Faculty, Trakia University, Stara Zag-
ora for work with humans in scientific projects (No 
4/2014). Informed consents were obtained from the 
patients before the study.
Isolation of DNA
Genomic DNA was isolated from 0.2 ml of 
whole blood using a commercial kit for isolation of 
genomic DNA from blood (GenElute™ Mammalian 
Genomic DNA Miniprep Kit, Sigma, USA).
Genotyping
The genotyping for MMP2 -1306 C>T 
(rs243865) was performed via PCR-RFLP-based 
methods as it was described earlier (18). Each reac-
tion with a total volume of 15μl, contained 1.5 μl of 
10x PCR buffer (with 25 mM MgCl2) (STS Ltd, Bul-
garia), 1.2 μl of 2.5 μmol/l  dNTPs (Fermentas), 0.6 U 
of Taq DNA polymerase (STS Ltd. Bulgaria), 7.6 pmol 
of each primer and 100 ng of DNA.  The sequenc-
es of the primers were as it follows: MMP2F: 5’-CTT 
CCT AGG CTG GTC CTT ACT GA-3’; MMP2R: 5’-
CTG AGA CCT GAA GAG CTA AAG AGC T-3’. 
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The temperature profile of the PCR reactions includ-
ed primary denaturing of template DNA for 5 min at 
94˚ C, followed by 30 cycles of denaturation for 30 sec 
at 94˚ C, annealing for 30 sec at 64˚ C and polymer-
ization for 30 sec at 72˚ C. The PCR reaction was ter-
minated by a final extension for 1 min at 72˚ C and 
for 1 min at 25˚C.  
The restriction reaction of 4 μl of each PCR 
product was carried out with 5U XspI (Fermentas) 
in a mix with a final volume of 15 μl for 16 h at 37˚ 
C. The fragments obtained after restriction reactions 
were analyzed on 10% Polyacrylamide gel electro-
phoresis (PAGE). 
The electrophoresis was performed in 1хТВЕ 
buffer with a field gradient of the electric current of 
10-20 V/cm for 3.5 hours. The gels were silver-stained 
and documented with a Gel documentation system 
(Syngene, Synoptics Ltd, UK). 
Statistical Analyses
Statistical analyses were performed using SPSS 
16.0 for Windows (SPSS Inc.). The ANOVA test was 
applied for comparing the continuous variables in 
independent groups. The Odds ratios (OR) were 
calculated by using an interactive Online Software 
Package at the web site http://statpages.org/#Package 
(http://statpages.org/ctab2x2.html). Factors with 
p<0.05 were considered statistically significant.
RESULTS
The PCR product amplified with the primers for 
MMP2 -1306 C>T SNP was of 193 bp in length. The 
XspI digestion resulted in 2 fragments with a length 
of 188 bp and 5 bp for allele C and in 3 fragments 
with a length of 162 bp, 26 bp and 5 bp for allele T 
(Figure 1).
The genotype, but not allele distribution of 
MMP2 -1306C>T, differed between COPD patients 
and controls (p=0.021 and p=0.602, respectively, Fig-
ure 2, Table 2). The genotypes containing the vari-
ant T allele (CT+TT) tended to be more common 
in COPD patients (35.7%) than in controls (25.4%, 
p=0.164), determining non-significantly 1.64-fold 
higher risk for COPD (OR=1.64, 95% CI: 0.82-3.26, 
Figure 3, Table 2). 
Characteristics Patients with COPD Controls 
Number
   males







Age at the inclusion in the study
   mean±SD (years)





Age at the diagnosis of the disease
   mean±SD (years)
   median (range) (years)
61.32±8.98
61 (34-83)
Duration of the disease
   mean±SD (years)




   non - smokers
   ex-smokers







4    (6%)
12  (19%)
Smoking habits (packs/year)
   mean±SD (years)












6    (7%)
Table 1. Demographic and clinical data of the patients with COPD and controls.
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The risk for COPD of T genotypes’ carriers 
was significant and even higher in the subset of 
older individuals (more than 65 years) (OR=4.24, 
95% CI: 1.31-13.57, p=0.019, Figure 4) and in those 
without diabetes as a co-morbidity (OR=3.48, 95% 
CI: 1.24-9.72, p=0.023, Figure 5). Such relation was 
not observed among individuals with diabetes 
(OR=0.481, 95% CI: 0.102-2.360, p=0.427)
Figure 1. PAGE for visualization of PCR-RFLP products 
and genotyping for MMP2 -1306C>T. The homozygous 
CC carriers were determined with one visible band of 188 
bp (41, 46, 49, 56, 57, 90, 97); the heterozygous CT carriers 
with two visible bands of 188 bp and 162 bp (28, 48), and 
the homozygous TT carriers – with one visible band of 
162 bp.
Figure 2. Genotype and allele distribution in COPD 
patients and controls




COPD patients Controls OR (95% CI), p-value
n frequency n frequency
n = 84 n = 71
Genotype frequency
CC 54 0.642 53 0.746 1.0 (referent)
CT 29 0.345 13 0.183 2.189 (1.04-4.62), p=0.045















-1306C 137 0.815 119 0.838 1.0 (referent)
-1306T 31 0.185 23 0.162 1.171 (0.65-2.11), p=0.654
Table 2. Genotype and allele frequencies of -1306C>T MMP2 SNP in COPD patients and control individuals.
Figure 4. Genotype distribution in patients with COPD 
above 65 years
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T genotypes (CT+TT) were associated with a 
later onset of the disease (mean of 64.11±7.12 years) 
than CC genotypes (59.74±9.54 years, p=0.045). No 
relations were found between the MMP2 -1306C>T 
genotypes and lung function indexes.
DISCUSSION
Smoking is the major risk factor for the devel-
opment of chronic obstructive pulmonary disease 
(COPD), and smoking cessation is the only effective 
way to slow down the disease progression (19-21).
Cigarette smokers develop some degree of lung 
inflammation, but the COPD patients develop a far 
greater degree of inflammation that progresses rap-
idly with the advance of the disease, often accompa-
nied by systemic inflammation and inflammation 
in the heart, blood vessels and skeletal muscle. The 
fact that only 10-20% of smokers develop severe de-
cline of the lung function and pathological chang-
es characteristic of COPD indicates participation of 
other etiological factors and the presence of predis-
posing genetic mechanisms of this disease (22). One 
of the main hypotheses for the development of path-
ological changes in COPD is protease-antiprote-
ase imbalance. According to this hypothesis the in-
creased number of cells which produce proteolytic 
enzymes (for example neutrophils and macrophages) 
in the lung and as well as the decreased synthesis of 
antiproteases, lead to uncontrolled proteolysis of the 
ECM and emphysema (8,23).
Matrix metalloproteinases, are zinc-dependent 
endopeptidases that participate in ECM degradation 
(2,14). In addition to the degradation of ECM, MMPs 
are involved in epithelial repair mechanisms and 
in the control of cytokine and chemokine activity. 
These features indicate an important role for MMPs 
in inflammatory processes. To date, 24 MMPs have 
been identified in mammals of which 23 are found 
in humans. On the basis of substrate specificity, se-
quence similarity, and domain organization, verte-
brate MMPs can be divided into six groups: Collage-
nases, Gelatinases, Stromelysins, Matrilysins, Mem-
brane-Type MMPs, and other MMPs, which are not 
classified in the above categories (14,24).MMP-2 to-
gether with MMP-9 is in the group of Gelatinases. 
MMP-2 (gelatinase-A) is constitutively expressed by 
many cell types including fibroblasts, keratinocytes, 
endothelial cells, chondrocytes. Gelatinases degrade 
a broad spectrum of ECM molecules such as col-
lagen types I, IV, V, VII, X, IX, elastin, fibronectin, 
aggrecan, vitronectin, laminin (25), but also many 
non-ECM molecules including pro-TNF-α, trans-
forming growth factor (TGF)-β, pro-IL-1β, pro-IL-8 
and monocyte chemoattractant protein (MCP)-3. 
MMP gene expression is primarily regulated at the 
transcriptional level, which usually results in low 
basal levels of these enzymes in normal physiological 
conditions (26-28). It has been found that in COPD 
patients alveolar macrophages, interstitial cells, 
and epithelial cells express gelatinase-A. Moreover, 
increased gelatinase-A was noticed in BAL fluid 
from COPD patients (29).
Several polymorphisms potentially affecting 
gene expression have been described in promoter 
regions of MMP. MMP-2 -1306C>T is a functional 
polymorphism and has been described to alter the 
transcriptional levels (18). Two DNA-protein com-
plexes were detected as binding to the C allele, but 
not the T allele, and additional competition experi-
ments combined with supershift analysis identified 
the protein binding to this region as Sp1. Transient 
transfection experiments showed that reporter gene 
expressions driven by the C allele were greater than 
reporter gene expressions driven by the T allele. So, 
the C>T polymorphism located at nucleotide -1306 
site disrupts an Sp1 regulatory element and thus, the 
T allele has a strikingly lower promoter activity com-
pared with the C allele (30).
In the present study we found that the geno-
type, but not allele distribution, differed between 
COPD patients and controls, as genotypes contain-
ing the variant T allele tended to be more common in 
Figure 5. Genotype distribution in patients with COPD 
without diabetes
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the group of patients. The carriage of the T allele de-
termines non-significantly 1.64-fold higher risk for 
developing COPD, as this risk turned out to be sig-
nificant in older individuals (over 65 years). These 
findings may lead to the hypothesis that other fac-
tors may play role in the gene expression of MMP-2. 
Even more immunohistochemical studies on human 
lung tissue show an increased expression of MMP-
2 in COPD patients (24,29). While it is well recog-
nized that MMP gene expression is mainly regulat-
ed at the transcriptional level, recent evidence, how-
ever, suggests that post-transcriptional mechanisms 
are also involved in the control of MMP expression 
in response to certain signals. As an example, TGF-β 
increases MMP-2 and -9 levels, mainly by extending 
the half-life of MMP mRNAs (26). Another impor-
tant point is that the oxidative stress, thought to be 
important in COPD, may also contribute to an ongo-
ing stimulus for MMP activation. The fact that spu-
tum neutrophilia is increased in advanced COPD 
and is associated with the presence of an accelerat-
ed decline in lung function should not be underesti-
mated (22,31).
On the other hand, COPD may develop not 
only due to emphysema, or increased destruction 
of ECM, but also due to airway obstruction. The 
chronic airflow limitation, characteristic of COPD, is 
caused by a mixture of small airway disease (obstruc-
tive bronchiolitis) and parenchymal destruction (em-
physema), the relative contributions of which vary 
from person to person (20). The extent of inflamma-
tion, fibrosis, and luminal exudates in small airways 
is correlated with the reduction in FEV1 and FEV1/
FVC ratio, and probably with the accelerated decline 
in FEV1 characteristic of COPD (20). Perhaps the 
lower promoter activity of the T allele may lead to in-
creased deposition of connective tissue in the lungs 
and development of airflow obstruction, which pos-
sibly is the reason for increased risk for development 
of COPD in older individuals.
The majority of studies have indicated that 
collagen content increases with age. There is also 
a change, with age, of the amount of the collagen 
types: decrease of type III collagen and increase of 
type I collagen. The observed alterations of the col-
lagen content have been shown to be concomitant 
with a decrease in MMP-1 and MMP-2 activity sug-
gesting that depression of the degradative path-
way may be partly responsible for age-related varia-
tions in the collagen in the lung (32). There has also 
been described an increase in matrix deposition in 
the adventitial compartments of the small airways 
and fibrosis accompanied by an accumulation of 
fibroblasts and myofibroblasts in those compart-
ments (22). The presence of fibrillar collagen raises 
the possibility that the collagen is contracted and 
leads to fixed airflow limitation by preventing the 
complete relaxation of the airway smooth muscle 
during hyperinflation or pharmacologically induced 
smooth muscle relaxation (22).
The results of our study showed that the car-
rying of T-containing genotypes (CT+TT) of MMP-
2 -1306C>T SNP may increase the risk of COPD in 
non-diabetic individuals, while such association was 
not found in those with diabetes as co-morbidities. 
There are no reported data in the literature support-
ing such observations. We suppose that in diabetic 
individuals the expression of MMPs is influenced by 
many other factors involved in the course of the dis-
ease which may confound the effect of genetic fac-
tors. That might be the explanation of the observed 
result that the studied SNP was a predisposing factor 
for COPD only in non-diabetic individuals. 
CONCLUSION
In conclusion, our results suggest that the 
carriers of T allele genotypes (CT+TT) of MMP2 
-1306C>T SNP may have higher risk for COPD in 
advanced age.
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